JP2024511851A5 - - Google Patents

Info

Publication number
JP2024511851A5
JP2024511851A5 JP2023560378A JP2023560378A JP2024511851A5 JP 2024511851 A5 JP2024511851 A5 JP 2024511851A5 JP 2023560378 A JP2023560378 A JP 2023560378A JP 2023560378 A JP2023560378 A JP 2023560378A JP 2024511851 A5 JP2024511851 A5 JP 2024511851A5
Authority
JP
Japan
Prior art keywords
mhfviii
amino acid
protein according
group
expression vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511851A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024916 external-priority patent/WO2022211791A1/en
Publication of JP2024511851A publication Critical patent/JP2024511851A/ja
Publication of JP2024511851A5 publication Critical patent/JP2024511851A5/ja
Pending legal-status Critical Current

Links

JP2023560378A 2021-03-30 2021-03-30 改変血漿凝固第ｖｉｉｉ因子およびその使用方法 Pending JP2024511851A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2021/024916 WO2022211791A1 (en) 2021-03-30 2021-03-30 Modified plasma clotting factor viii and method of use thereof

Publications (2)

Publication Number Publication Date
JP2024511851A JP2024511851A (ja) 2024-03-15
JP2024511851A5 true JP2024511851A5 (https=) 2024-04-12

Family

ID=75588282

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560378A Pending JP2024511851A (ja) 2021-03-30 2021-03-30 改変血漿凝固第ｖｉｉｉ因子およびその使用方法

Country Status (4)

Country Link
EP (1) EP4314041A1 (https=)
JP (1) JP2024511851A (https=)
CN (1) CN117157316A (https=)
WO (1) WO2022211791A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4501729A (en) 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
AU780231B2 (en) 1998-11-10 2005-03-10 University Of North Carolina At Chapel Hill, The Virus vectors and methods of making and administering the same
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
ATE318923T1 (de) 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
PL206105B1 (pl) 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1233064A1 (en) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modified factor VIII cDNA and its use for the production of factor VIII
AU2003249208B2 (en) 2002-07-16 2010-03-04 Vgx Pharmaceuticals, Llc Codon optimized synthetic plasmids
EP1424344A1 (en) 2002-11-29 2004-06-02 Aventis Behring Gesellschaft mit beschränkter Haftung Modified cDNA factor VIII and its derivates
SE536732C2 (sv) 2011-03-04 2014-07-01 Swemac Innovation Ab Protes för steloperation av en led
LT3013855T (lt) * 2013-06-24 2021-01-25 Xiao, Weidong Mutavusio viii faktoriaus kompozicijos ir metodai
CN112119158A (zh) * 2018-04-12 2020-12-22 生物测试股份公司 去免疫化的因子viii分子以及包含其的药物组合物
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體

Similar Documents

Publication Publication Date Title
US20250066813A1 (en) Means and method for preparing viral vectors and uses of same
US20220331409A1 (en) Factor ix gene therapy
AU2019228504B2 (en) Novel adeno-associated virus (AAV) vectors, AAV vectors having reduced capsid deamidation and uses therefor
US10786568B2 (en) AAV mediated influenza vaccines
KR102063483B1 (ko) Ａａｖ 캡시드 변이체를 이용한 고효율 유전자 전달을 위한 조성물 및 방법
EP3024498B1 (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
JP2025114562A (ja) 非組み込みウイルス送達システムおよびその使用の方法
CA3091806A1 (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
KR20170084012A (ko) 지혈 장애의 치료를 위한 변이체 인자 viii의 패키징 및 발현을 위한 개선된 발현 카세트
CN111718947B (zh) 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途
CN113747926A (zh) 用于肌肉表达的杂合启动子
US11077208B2 (en) Wilson's disease gene therapy
WO2022139631A1 (en) Aav5-based vaccine for induction of specific immunity and/or prevention of sars-cov-2-related infection
KR20240063110A (ko) 치료제의 역행성 관상 정맥 또는 정맥동 투여
JP2024511851A5 (https=)
CN117660370B (zh) 一种重组腺相关病毒、抗炎药物及其在脓毒性脑病治疗中的应用
RU2818529C2 (ru) Средства и способ получения вирусных векторов и варианты их применения
JP2024515623A (ja) 髄腔内送達によってピット・ホプキンス症候群を治療するためのメチル－ｃｐｇ結合タンパク質２をコードする組換えアデノ随伴ウイルス
KR20260052185A (ko) 바이러스 벡터를 제조하기 위한 수단 및 방법 및 그의 용도
HK1223849B (en) Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues